Mevo Turns Prescriptions Into a Platform and Investors are Doubling Down with R$ 95 Million Round Equity Finance

Mevo funding round signals renewed investor conviction in Brazil’s digital prescription infrastructure

Mevo funding round signals strong investor conviction in Brazil’s digital prescription infrastructure, as the company secured R$ 95 million in fresh capital to expand its marketplace and healthcare platform.

The round represents an extension of Mevo’s Series B and was led by Prosus, with participation from existing investors including Matrix, Jefferson River Capital, Lyrical, Floating Point, and Verônica Serra. It follows the company’s R$110 million Series B in 2024 and subsequent extensions, bringing total capital raised to more than R$300 million. This Mevo healthtech funding expansion reflects growing confidence in infrastructure driven healthtech models.

Why this deal matters for Brazil healthtech

This is not simply incremental capital. It is a strong insider led signal.

Prosus, already an investor, increased its exposure after Mevo delivered on operational targets and scaled its platform across hospitals and physicians. The Mevo funding round also highlights how insider capital is increasingly tied to execution milestones.

More broadly, the deal reinforces a trend in which investors are doubling down on infrastructure platforms with proven distribution and monetization pathways.

How Mevo scales prescription monetization

Mevo operates a digital prescription platform that connects doctors, patients, and pharmacies into a single ecosystem. Hospitals and physicians use the system at no cost, while monetization occurs downstream through its marketplace and pharmaceutical partnerships.

This Mevo healthtech funding model positions the company closer to a transaction driven infrastructure layer than a traditional SaaS business. Revenue scales with prescription volume, creating stronger long term unit economics.

The strategy follows a familiar pattern in platform businesses capture distribution first then monetize conversion.

The Firms Behind the Deal

On the company side, Mevo turned to cross border counsel spanning the United States and offshore jurisdictions. 

Foley & Lardner LLP acted as U.S. legal advisor to Mevo, with Silicon Valley partner Andre Thiollier leading the deal team alongside Trevor Mullin, Bella Tappin, and Nicholas Fletcher.

Cayman counsel was provided by Conyers Dill & Pearman, where Nicholas Pattman advised on structuring matters.

On the investor side, Prosus was represented by Gunderson Dettmer, with partner Christel H. Moreno leading the mandate, supported by Eduarda Tavares and Stefania Gomes Toschi. Brazilian counsel to Prosus was provided by Demarest Advogados, with partners Juliana Maluf and Beatriz Seixas advising on local law aspects.

Matrix Partners, one of Mevo’s key existing investors, was advised by Goodwin Procter LLP. The deal team was led by Luke Neveu, with support from Matthew Reardon, Matthew Kane, and David Cappillo.

A Silicon Valley legal stack behind the Mevo funding round

This transaction stands out for the concentration of top tier U.S. venture counsel across both sides of the table. Firms such as Foley and Lardner, Gunderson Dettmer, and Goodwin Procter continue to play a central role in structuring late stage Brazilian venture deals, particularly where international investors and offshore structures are involved.

This reinforces a broader pattern in cross border venture execution where Silicon Valley legal infrastructure remains deeply embedded in Brazilian transactions.

Why Mevo healthtech funding signals long term positioning

The Mevo funding round ultimately reflects conviction rather than necessity.

By strengthening its position between prescription, commerce, and pharmaceutical distribution, Mevo is evolving into a core layer of Brazil’s healthcare system. This Mevo healthtech funding reinforces the company’s transition from product to infrastructure, with monetization tied to real transactions and a growing installed base.

Related Reading

For more on Mevo’s earlier financing and legal structuring, see our previous coverage:

• Mevo Raises $20 Million Series B Round Led by Investment Fund Matrix
• From Digital Prescription to Backbone Pharmacy, Mevo Raises $45 Million (BRL) from Floating Point

Resumo em português

A Mevo levantou R$95 milhões em uma extensão da Série B liderada pela Prosus para expandir sua plataforma de prescrição digital e marketplace de medicamentos no Brasil. O aporte reforça a confiança dos investidores no modelo baseado em monetização após a prescrição.